Teva Pharmaceutical Industries announced that Dr. Eric Hughes, Executive Vice President of Global R&D and Chief Medical Officer, has resigned from the company effective November 17, 2026. The company has initiated a search for a successor and stated that its 'Pivot to Growth' strategy, R&D priorities, and financial expectations remain unchanged.
Key Details
- Departure: Dr. Eric Hughes has stepped down from his role immediately but will remain with Teva for a few months to ensure a smooth transition.
- Interim Leadership: Dr. David Gardiner, Head of Innovative Medicines & Clinical Development, will serve as the transition lead for R&D, reporting directly to the CEO.
- Strategic Outlook: Teva reaffirmed its commitment to its strategy and its goal of generating $6–7 billion in innovative medicines revenue by 2030.